Leuprolide Acetate Kit
NDC Package 70710-1769-3
Package Information
Leuprolide Acetate kits is leuprolide is used to treat advanced prostate cancer in men. This formulation utilizes a kit delivery system. Marketed by Zydus Pharmaceuticals Usa Inc., this product is identified by NDC 70710-1769 and is authorized under FDA application ANDA215826.
Identification & Billing
- RxCUI: 545835 - leuprolide acetate 1 MG/0.2 ML (5 MG/ML) Injectable Solution
- RxCUI: 545835 - leuprolide acetate 5 MG/ML Injectable Solution
- RxCUI: 545835 - leuprolide acetate 1 MG per 0.2 ML Injectable Solution
- RxCUI: 797544 - isopropyl alcohol 70 % Medicated Pad
- RxCUI: 797544 - isopropyl alcohol 0.7 ML/ML Medicated Pad
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70710 - Zydus Pharmaceuticals Usa Inc.
- 70710-1769 - Leuprolide Acetate
- 70710-1769-3 - 1 KIT in 1 CARTON * 1 VIAL, MULTI-DOSE in 1 CARTON (70710-1768-1) / 2.8 mL in 1 VIAL, MULTI-DOSE * 1 mL in 1 PACKET (70710-1897-8)
- 70710-1769 - Leuprolide Acetate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70710-1769-3 identifies a specific commercial package of 1 kit in 1 carton * 1 vial, multi-dose in 1 carton (70710-1768-1) / 2.8 ml in 1 vial, multi-dose * 1 ml in 1 packet (70710-1897-8) of Leuprolide Acetate, a human prescription drug labeled by Zydus Pharmaceuticals Usa Inc.. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on January 08, 2026. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Leuprolide is used to treat advanced prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Leuprolide works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells and helps relieve symptoms such as painful/difficult urination. Talk to your doctor about the risks and benefits of treatment. Leuprolide is also used to stop early puberty (precocious puberty) in children. It helps to delay sexual development (such as growth of the breasts/testicles) and the start of menstrual periods. It also helps slow down early bone growth to increase the likelihood of reaching normal adult height. Leuprolide works by decreasing the amount of sex hormones that a child's body makes (estrogen in girls, testosterone in boys).
How is this Zydus Pharmaceuticals Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710176903. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.